JP2000026301A - Therapeutic agent for dermatosis - Google Patents
Therapeutic agent for dermatosisInfo
- Publication number
- JP2000026301A JP2000026301A JP10228482A JP22848298A JP2000026301A JP 2000026301 A JP2000026301 A JP 2000026301A JP 10228482 A JP10228482 A JP 10228482A JP 22848298 A JP22848298 A JP 22848298A JP 2000026301 A JP2000026301 A JP 2000026301A
- Authority
- JP
- Japan
- Prior art keywords
- ingredient
- skin
- effective against
- ointment
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は皮膚疾患治療薬に関し、
特に、アトピー性皮膚炎等の皮膚疾患のある部分に塗布
して使用し、細菌、真菌に効果があり、患部の角質層が
剥がれ易くなり、薬剤が沁み込み易くした皮膚疾患治療
薬に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic agent for skin diseases,
In particular, the present invention relates to a drug for treating a skin disease which is applied to a portion having a skin disease such as atopic dermatitis and is effective against bacteria and fungi, the horny layer of an affected part is easily peeled off, and the drug is easily infiltrated.
【0002】[0002]
【従来の技術】最近、特に、アトピー体質の子供が増え
ていると同時に、思春期以降になっても、治らないこと
が多くなっている。また、子供のころにはそうでもなか
ったのに、思春期以降アトピー体質になり、アトピー性
皮膚炎を起こすことも増えているといわれている。その
アトピー性皮膚炎の治療には、一般にステロイド系薬剤
が使用されており、そのステロイド系薬剤は現在、アト
ピー性皮膚炎に最も効果があり、痒みや炎症を押さえる
ことができるが、他方、その副作用が大きいという欠点
がある。したがって、そのような副作用のない外用薬剤
が求められる。2. Description of the Related Art In recent years, in particular, the number of children having an atopic constitution has been increasing, and at the same time, even after puberty, it is often difficult to heal. It is said that, although they were not so early in their childhood, they have become atopic since puberty and are more likely to cause atopic dermatitis. Steroids are commonly used in the treatment of atopic dermatitis, and these steroids are currently the most effective for atopic dermatitis and can reduce itching and inflammation. There is a disadvantage that side effects are large. Therefore, there is a need for a topical drug that does not have such side effects.
【0003】[0003]
【発明が解決しようとする課題】そこで、東京医科大学
教授の徳田安章氏によれば、アトピー体質の第一の特徴
は、皮膚の脂肪の分泌が少ないことである。正常な皮膚
は二重の脂肪の膜によって保護され、潤いが与えられる
のであるが、アトピー体質の場合、脂肪の分泌が少ない
ので皮膚に潤いがなくなり、保護機能も低下し、傷つき
やすくなり、外から異物が侵入しやすくなる。アトピー
体質の第二の特徴は、皮膚の最外層の角層の角化傾向で
ある。このために、皮膚の表面や毛穴が突出してざらつ
き、そのために、さらに傷つき易くなる。アトピー体質
の第三の特徴は、出てきた汗を角層が吸い取ってしまう
ので汗がうまく皮膚の外へ出て行かないことである。角
層を構成する角質はもともと水分を非常によく吸収する
性質を持っているが、通常は脂肪が適度にあるために、
汗を吸収することなく皮膚の外に出している。しかし、
脂肪が少なく、しかも角化傾向があるアトピー体質で
は、角層が汗を吸い込むので角層がふやけて汗管をつぶ
してしまう。そこへさらに汗が出てきても、汗は外へ出
られないのでそこに汗もが簡単にできてしまう。汗もが
できると、そこが水ぶくれになったり、かゆいためにか
いたりして、皮膚に傷をつけることになり、そこから異
物が侵入してしまう。このように、アトピー体質では、
脂肪の分泌が少ないこと、角層の角化傾向、汗の分泌が
しにくいことが、皮膚が傷つき易く、異物が外から皮膚
の内側に侵入し易い状況を作り出すのである。そのため
に、ダニや花粉など空中に浮遊する物質に対してアレル
ギー反応を起こす機会が非常に多くなるのである。その
ために、本発明は脂肪の分泌不足を外から補い、皮膚に
潤いを与え、かゆみを止め、角層の角化傾向を緩和する
ことによって、皮膚が傷ついて、異物が外から皮膚の内
側に侵入し易い状態を防止するとともに、細菌、真菌類
の繁殖を抑え、副作用を生じさせることなく、アトピー
性皮膚炎に効果を表す皮膚疾患治療薬を提供することを
課題とする。According to Yasuaki Tokuda, a professor at Tokyo Medical University, the first feature of the atopic constitution is that the skin secretes less fat. Normal skin is protected and moisturized by the double fat film.However, in the case of atopic constitution, since the secretion of fat is small, the skin is not moistened, the protective function is reduced, the skin is easily damaged, Foreign matter is easily invaded from the surface. The second feature of atopic constitution is the tendency of the outermost stratum corneum of the skin to keratinize. For this reason, the surface and pores of the skin protrude and become rough, which makes the skin more easily damaged. The third characteristic of atopic constitution is that sweat does not go well out of the skin because the stratum corneum absorbs the sweat that has come out. The stratum corneum that originally makes up the stratum corneum has the property of absorbing water very well, but usually because of the moderate amount of fat,
Has gone out of the skin without absorbing sweat. But,
In atopic constitutions that have less fat and tend to be keratinized, the stratum corneum absorbs sweat, so that the stratum corneum swells and crushes the sweat tube. Even if there is more sweat, there is no way to get out of the sweat, so sweat can easily form there. When sweat is formed, the skin becomes blistered or itchy, causing skin injuries and foreign substances invading there. Thus, in atopic constitution,
Low secretion of fat, keratinization of the stratum corneum, and difficulty in secreting sweat create a situation in which the skin is easily damaged and foreign substances easily enter the inside of the skin from the outside. As a result, the chances of causing an allergic reaction to airborne substances such as mites and pollen are greatly increased. Therefore, the present invention supplements the lack of secretion of fat from the outside, moisturizes the skin, stops itching, and reduces the keratinization tendency of the stratum corneum. An object of the present invention is to provide a remedy for a skin disease which is effective for atopic dermatitis, while preventing a state that is easily invaded, suppressing the growth of bacteria and fungi, and causing no side effects.
【0004】[0004]
【課題を解決するための手段】本発明は、塩化アセチル
コリンと、安息香酸ソーダカフェインと、塩酸オキシテ
トラサイクリンと、トリコマイシンとを含む軟膏からな
る皮膚疾患治療薬である。DISCLOSURE OF THE INVENTION The present invention is a remedy for skin diseases comprising an ointment containing acetylcholine chloride, sodium benzoate oxytetracycline, and tricomycin.
【0005】[0005]
【作用】本発明は、塩化アセチルコリンを25g、安息
香酸ソーダカフェインを25g、塩酸オキシテトラサイ
クリンを1000mg、トリコマイシンを50万単位と
クロラムフェニコールを250mgとを含む軟膏からな
る皮膚疾患治療薬であるところ、塩化アセチルコリン
は、皮膚のかゆみをとる作用があり、安息香酸ソーダカ
フェインは、角質層を軟化させて剥れ易くする。塩酸オ
キシテトラサイクリンは、テラマイシン(ファイザー製
薬株式会社)注射液の主成分であり、ぶどう球菌、レン
サ球菌、大腸菌等に有効である。トリコマイシンとクロ
ラムフェニコールは、トリコマイシンK錠(藤沢薬品工
業株式会社)に含まれる抗生物質であって、トリコマイ
シンはトリコモナスやカンジダのような真菌に効き、ク
ロラムフェニコールは、ぶどう球菌、大腸菌などに対し
て発育阻止作用を有する。かくして、これらの薬効を持
つ成分を含む軟膏を、アトピー性皮膚炎の患部に塗る
と、軟膏が皮膚の表皮を保護し、潤いを与える。かゆみ
には塩化アセチルコリンが働き、皮膚のかゆみをとる。
同時に、安息香酸ソーダカフェインが角質層を軟化させ
て剥れ易くし、薬剤が浸透してその効きめをあげるよう
に働く。他方、このアトピー性皮膚炎は細菌が繁殖し易
く、化膿を引き起こすこともある。その原因は黄色ぶど
う球菌であるが、ここでクロラムフェニコールがその殺
菌を行う。また、その患部には、真菌も繁殖し易い状態
にあるが、これには、トリコマイシンが作用してその殺
菌を行う。この軟膏を繰り返し患部に塗ることによりア
トピー性皮膚炎の治療効果を上げることができる。The present invention is a remedy for skin diseases comprising an ointment containing 25 g of acetylcholine chloride, 25 g of sodium benzoate, 1000 mg of oxytetracycline hydrochloride, 500,000 units of tricomycin and 250 mg of chloramphenicol. However, acetylcholine chloride has the effect of removing the itch of the skin, and sodium benzoate benzoate softens the stratum corneum and makes it easier to peel off. Oxytetracycline hydrochloride is the main component of terramycin (Pfizer Pharmaceutical Co., Ltd.) injection and is effective against staphylococci, streptococci, Escherichia coli and the like. Tricomycin and chloramphenicol are antibiotics contained in Tricomycin K tablets (Fujisawa Pharmaceutical Co., Ltd.). Tricomycin is effective against fungi such as Tricomonas and Candida. Against growth. Thus, when an ointment containing these medicinal ingredients is applied to the affected area of atopic dermatitis, the ointment protects the skin epidermis and moisturizes it. Acetylcholine chloride works for itching, and itchy skin.
At the same time, sodium caffeine benzoate softens the stratum corneum, making it easier to peel off, and works to penetrate the drug and increase its effectiveness. On the other hand, this atopic dermatitis is easy for bacteria to multiply and may cause suppuration. The cause is Staphylococcus aureus, where chloramphenicol kills it. The affected area is also in a state where fungi can easily proliferate. Tricomycin acts on the affected area to sterilize it. By repeatedly applying this ointment to the affected area, the therapeutic effect of atopic dermatitis can be improved.
【0006】[0006]
【実施例1】本発明は、塩化アセチルコリンを25g、
安息香酸ソーダカフェインを25g、塩酸オキシテトラ
サイクリンを1000mg、トリコマイシンを50万単
位とクロラムフェニコールを250mgとを含む軟膏か
らなる皮膚疾患治療薬であって、塩化アセチルコリンを
25gと、安息香酸ソーダカフェインを25gと、テラ
マイシン(ファイザー製薬株式会社)注射液20ml
(塩酸オキシテトラサイクリン1000mg含有)と、
トリコマイシンK錠(藤沢薬品工業株式会社)10錠
(トリコマイシンを50万単位とクロラムフェニコール
を250mgを含む)とを混合して、それを白色ワセリ
ンに配合し軟膏にする。この場合、基剤は白色ワセリン
に制限されるものではない。ここに示した薬剤成分の分
量は、この数値に制限されるものではないけれども、実
験の結果、この数値の軟膏が最もすぐれた効果を表し
た。Example 1 The present invention relates to a method for preparing 25 g of acetylcholine chloride,
A skin disease therapeutic agent comprising an ointment containing 25 g of sodacaffeine benzoate, 1000 mg of oxytetracycline hydrochloride, 500,000 units of tricomycin and 250 mg of chloramphenicol, wherein 25 g of acetylcholine chloride and 25 g of sodium benzoate are added. 25g and Teramycin (Pfizer Pharmaceutical Co., Ltd.) Injection 20ml
(Containing 1000 mg of oxytetracycline hydrochloride),
Tricomycin K tablets (Fujisawa Pharmaceutical Co., Ltd.) are mixed with 10 tablets (containing 500,000 units of tricomycin and 250 mg of chloramphenicol) and mixed with white petrolatum to form an ointment. In this case, the base is not limited to white petrolatum. Although the amount of the drug component shown here is not limited to this value, as a result of the experiment, the ointment having this value showed the best effect.
【0007】[0007]
【効果】本発明は、塩化アセチルコリンを25g、安息
香酸ソーダカフェインを25g、塩酸オキシテトラサイ
クリンを1000mg、トリコマイシンを50万単位と
クロラムフェニコールを250mgとを含む軟膏からな
る皮膚疾患治療薬であるので、その中に配合されたそれ
ぞれの成分の薬効により、患部の脂肪の分泌不足を外か
ら補い、皮膚に潤いを与え、かゆみを止め、角層の角化
傾向を緩和することによって、皮膚が傷ついて、異物が
外から皮膚の内側に侵入し易い状態を防止するととも
に、細菌、真菌類の繁殖を抑え、アトピー性皮膚炎に非
常に効き目があるという効果がある。さらに、ステロイ
ド系薬剤にみられる副作用がないという効果がある。The present invention is a remedy for skin diseases comprising an ointment containing 25 g of acetylcholine chloride, 25 g of sodium benzoate, 1000 mg of oxytetracycline hydrochloride, 500,000 units of tricomycin and 250 mg of chloramphenicol. Because of the medicinal properties of each of the ingredients in it, the lack of secretion of fat in the affected area is compensated from the outside, the skin is moisturized, itching is stopped, and the keratinization of the stratum corneum is eased. It prevents wounds and foreign substances from easily entering the inside of the skin from the outside, suppresses the growth of bacteria and fungi, and is very effective in atopic dermatitis. Furthermore, there is an effect that there is no side effect seen in steroid drugs.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/65 A61K 31/65 Fターム(参考) 4C076 AA08 BB31 CC18 CC32 DD34 DD60 FF67 4C086 AA01 CA03 CB07 DA29 MA03 MA04 MA28 MA63 ZA89 ZB13 ZB35 4C206 AA01 EA02 FA42 MA03 MA04 MA48 MA83 ZA89 ZB13 ZB35──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 31/65 A61K 31/65 F-term (Reference) 4C076 AA08 BB31 CC18 CC32 DD34 DD60 FF67 4C086 AA01 CA03 CB07 DA29 MA03 MA04 MA28 MA63 ZA89 ZB13 ZB35 4C206 AA01 EA02 FA42 MA03 MA04 MA48 MA83 ZA89 ZB13 ZB35
Claims (2)
フェインと、塩酸オキシテトラサイクリンと、トリコマ
イシンとを含む軟膏からなる皮膚疾患治療薬。1. A remedy for skin diseases comprising an ointment containing acetylcholine chloride, sodium caffeine benzoate, oxytetracycline hydrochloride, and tricomycin.
ーダカフェインを25g、塩酸オキシテトラサイクリン
を1000mg、トリコマイシンを50万単位とクロラ
ムフェニコールを250mgとを含む軟膏からなる請求
項1記載の皮膚疾患治療薬。2. The treatment of skin diseases according to claim 1, comprising an ointment containing 25 g of acetylcholine chloride, 25 g of sodium benzoate, 1000 mg of oxytetracycline hydrochloride, 500,000 units of tricomycin and 250 mg of chloramphenicol. medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10228482A JP2000026301A (en) | 1998-07-09 | 1998-07-09 | Therapeutic agent for dermatosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10228482A JP2000026301A (en) | 1998-07-09 | 1998-07-09 | Therapeutic agent for dermatosis |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000026301A true JP2000026301A (en) | 2000-01-25 |
Family
ID=16877169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10228482A Pending JP2000026301A (en) | 1998-07-09 | 1998-07-09 | Therapeutic agent for dermatosis |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2000026301A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1396261A1 (en) * | 2002-09-06 | 2004-03-10 | Alcina Cosmetic, Dr. Kurt Wolff GmbH & Co.KG | Skincare composition containing caffeine |
EP1262169A3 (en) * | 2001-05-29 | 2004-05-06 | L'oreal | Skin anti-ageing composition |
-
1998
- 1998-07-09 JP JP10228482A patent/JP2000026301A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1262169A3 (en) * | 2001-05-29 | 2004-05-06 | L'oreal | Skin anti-ageing composition |
EP1396261A1 (en) * | 2002-09-06 | 2004-03-10 | Alcina Cosmetic, Dr. Kurt Wolff GmbH & Co.KG | Skincare composition containing caffeine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2381925B1 (en) | Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin | |
WO2018107130A1 (en) | Composition for treating wounds and other dermatological conditions | |
AU2017250267A1 (en) | Compositions for topical application of compounds | |
Garrido et al. | Gonyautoxin: new treatment for healing acute and chronic anal fissures | |
JP2003514875A (en) | Propellant-free spray-on skin patch composition for improving wound healing and administering medication | |
EP1011610A1 (en) | Skin care compositions and use | |
US8846646B2 (en) | Topical treatment of skin infection | |
WO1991007974A1 (en) | Topical therapeutic preparation | |
KR101642537B1 (en) | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it | |
Happle et al. | Systemic retinoid therapy of systematized verrucous epidermal nevus | |
BRPI0413474A (en) | interferon and ribavirin use and kit for use in the treatment of viral infections | |
US20140271920A1 (en) | Skin ointment formulation | |
JP2000026301A (en) | Therapeutic agent for dermatosis | |
Mishra et al. | Topical antibiotics and semisolid dosage forms | |
JPH03227921A (en) | Remedy for keloid | |
RU2536266C2 (en) | Cream for medicinal purposes, made with application of framycetin sulfate and chitosan | |
US20040156870A1 (en) | Use of urea as a method for improving the effectiveness of topical anti-inflammatory drugs | |
RU2440108C2 (en) | Pharmaceutical composition for allergic and inflammatory skin diseases | |
Frost et al. | Clinical Comparison of Alclometasone Dipropionate and Desonide Ointments (0· 05%) in the Management of Psoriasis | |
WO2003097070A1 (en) | The pharmaceutical composition comprising a corticosteroid and an antiseptic | |
EP3348307A1 (en) | Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis, vitiligo e rosacea | |
Fraser et al. | Treatment of acne vulgaris comparing two similar lotion formulations, one with (‘Actinac’) and one without chloramphenicol | |
CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
US20030114534A1 (en) | Pharmaceutical preparation for apthous ulcers | |
WO2023021493A1 (en) | Method for treatment of rosacea in patients aged 35-64 years |